304 related articles for article (PubMed ID: 38612592)
1. Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.
Kashyap D; Salman H
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612592
[TBL] [Abstract][Full Text] [Related]
2. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
3. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
Dees S; Ganesan R; Singh S; Grewal IS
Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo.
Leland P; Degheidy H; Lea A; Bauer SR; Puri RK; Joshi BH
Clin Transl Med; 2024 May; 14(5):e1664. PubMed ID: 38685487
[TBL] [Abstract][Full Text] [Related]
5. Gastrodin synergistically increases migration of interleukin-13 receptor α2 chimeric antigen receptor T cell to the brain against glioblastoma multiforme: A preclinical study.
Huang S; Bai Y; An Z; Xu C; Zhang C; Wang F; Zhong C; Zhong X
Phytother Res; 2023 Dec; 37(12):5947-5957. PubMed ID: 37748098
[TBL] [Abstract][Full Text] [Related]
6. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
7. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
Front Immunol; 2022; 13():867154. PubMed ID: 35603195
[TBL] [Abstract][Full Text] [Related]
8. T cells redirected to EphA2 for the immunotherapy of glioblastoma.
Chow KK; Naik S; Kakarla S; Brawley VS; Shaffer DR; Yi Z; Rainusso N; Wu MF; Liu H; Kew Y; Grossman RG; Powell S; Lee D; Ahmed N; Gottschalk S
Mol Ther; 2013 Mar; 21(3):629-37. PubMed ID: 23070117
[TBL] [Abstract][Full Text] [Related]
9. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress.
Corti C; Venetis K; Sajjadi E; Zattoni L; Curigliano G; Fusco N
Expert Opin Investig Drugs; 2022 Jun; 31(6):593-605. PubMed ID: 35311430
[TBL] [Abstract][Full Text] [Related]
10. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.
Knudson KM; Hwang S; McCann MS; Joshi BH; Husain SR; Puri RK
Front Immunol; 2022; 13():878365. PubMed ID: 35464460
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy.
Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478
[TBL] [Abstract][Full Text] [Related]
13. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
14. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
Hegde M; Corder A; Chow KK; Mukherjee M; Ashoori A; Kew Y; Zhang YJ; Baskin DS; Merchant FA; Brawley VS; Byrd TT; Krebs S; Wu MF; Liu H; Heslop HE; Gottschalk S; Yvon E; Ahmed N
Mol Ther; 2013 Nov; 21(11):2087-101. PubMed ID: 23939024
[TBL] [Abstract][Full Text] [Related]
15. IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas.
Killock D
Nat Rev Clin Oncol; 2024 May; 21(5):335. PubMed ID: 38514882
[No Abstract] [Full Text] [Related]
16. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
Choi BD; Curry WT; Carter BS; Maus MV
Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
[TBL] [Abstract][Full Text] [Related]
17. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers.
Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C
Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762
[TBL] [Abstract][Full Text] [Related]
18. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
Front Immunol; 2020; 11():573823. PubMed ID: 33072116
[TBL] [Abstract][Full Text] [Related]
19. CAR T-cell therapy for triple-negative breast cancer: Where we are.
Xie Y; Hu Y; Zhou N; Yao C; Wu L; Liu L; Chen F
Cancer Lett; 2020 Oct; 491():121-131. PubMed ID: 32795486
[TBL] [Abstract][Full Text] [Related]
20. Novel immunotherapies for breast cancer: Focus on 2023 findings.
Lan HR; Chen M; Yao SY; Chen JX; Jin KT
Int Immunopharmacol; 2024 Feb; 128():111549. PubMed ID: 38266449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
